Evotec's Restructuring Pivot: A Painful Prescription for Future Growth

Evotec posts solid 2025 results but forecasts a sharp 2026 profit drop due to a major restructuring plan, while activist investors push for a Biologics spin-off.

Investors in German drug discovery firm Evotec SE have received a stark diagnosis for the coming year. While the company delivered solid 2025 results, its 2026 forecast reveals a period of significant financial pain as a major corporate overhaul takes hold. The market's initial reaction, however, suggests shareholders are willing to swallow the bitter pill, betting the deep cuts will restore long-term health.

The company closed its 2025 fiscal year near the top of its guidance range, posting group revenue of €788.4 million. Its adjusted EBITDA came in at €41.1 million. Yet a look beneath the surface reveals a business operating in two distinct realities. The historic core business, Drug Discovery and Preclinical Development (D&PD), struggled with a 13.5% revenue decline. In stark contrast, the Just – Evotec Biologics unit shone brightly, boosting its sales by 39% to €259.4 million and currently stands as the group's sole profitable segment.

This imbalance is the driving force behind the radical "Horizon" transformation program launched in March. The plan is a surgical one: Evotec will shrink its global footprint from 14 sites to 10 by the end of 2027 and eliminate approximately 800 jobs, with the majority of cuts occurring this year. Management expects these measures to yield annual cost savings of around €75 million once fully implemented.

The financial toll for this restructuring will be immediate and severe. For the full year 2026, Evotec anticipates revenue between €700 million and €780 million—a clear step down—and an adjusted EBITDA ranging from zero to just €40 million. This outlook fell dramatically short of analyst expectations, which had hovered above €80 million. The company has earmarked roughly €100 million in restructuring costs for the second half of 2026 alone.

To navigate this cash-intensive transition, Evotec is bolstering its liquidity. A key lifeline is the pending sale of Tubulis to Gilead Sciences, expected to close in the second quarter of 2026. The deal will bring an upfront payment of approximately $100 million, with the potential for up to $58 million more in milestone-dependent payments.

The aggressive restructuring comes amid mounting pressure from a key shareholder. Activist investor MAK Capital, a major stakeholder, is vocally advocating for a separate U.S. listing of the profitable Biologics subsidiary. The investor believes such a move could unlock a valuation exceeding one billion euros and attract fresh capital.

Leadership is also undergoing a shift. Dr. Ashiq H. Khan was appointed Chief Commercial Officer in early April. All eyes are now on the Annual General Meeting scheduled for June 11, where industry veteran Dieter Weinand is slated to be elected as the new Chairman of the Supervisory Board. This meeting will be a critical forum for management to balance the weak annual guidance with the ambitious demands of its shareholders.

Despite the daunting near-term forecast, Evotec's management reaffirmed its medium-term ambitions. The company is targeting annual revenue growth of 8% to 12% through 2030 and aims to achieve an adjusted EBITDA margin of 20% by 2028. For now, the stock trades roughly 46% below its 52-week high, indicating the market is still waiting for concrete proof that the "Horizon" program will deliver on its promise.